PK IDIQ- Post-market Bioequivalence of Generic Drug Products
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The Food and Drug Administration is issuing a forecast for an Indefinite Delivery Indefinite Quantity contract focused on the post-market bioequivalence of generic drug products. This initiative falls under NAICS code 541714, indicating a focus on research and development in the biotechnology and pharmaceutical fields. The contract is managed by the Food and Drug Administration, with the Cder Acquisition Liaison serving as the primary program point of contact. While specific solicitation details and set-aside designations are not yet provided, the project aims to support the agency's oversight of generic drug performance and safety through bioequivalence testing.
General Info
Place of Performance
USASet-Aside
Documents
0AI Contract Breakdown
Uniform Contract FormatNo documents to break down
The breakdown needs solicitation documents. None were found from this contract's source.
Organization & Contact Information
Full Description
Similar Contracts
Same NAICS industry code
Prepare for this forecast
Research this forecast and prepare for the solicitation
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 750+ contractors already using CLEATUS
